Home > Insider Trading > Filing (0001209191-20-054320)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1671818	Oncorus Inc.	ONCR	Pharmaceutical Preparations (2834)	473779757

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1687078	Mpm Oncology Impact Management Lp	C/O Mpm Asset Management Llc 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1691428	L.p. Fund Impact Oncology Ubs	Ubs Trustees (Cayman) Ltd 5Th Fl Cayman Corp Center 27 Hospital George Town E9 KY1-1106	No	No	Yes	No
1721035	Mpm Oncology Impact Management Gp Llc	C/O Mpm Asset Management Llc 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1721036	L.p. Management (Cayman) Fund Impact Oncology	Ubs Trustees (Cayman) Ltd 5Th Fl Cayman Corp Center 27 Hospital George Town E9 KY1-1106	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-10-06	1,525,348	$0.00	1,525,348	No	4	C	Direct
Common Stock	Acquisiton	2020-10-06	700,453	$0.00	2,225,801	No	4	C	Direct
Common Stock	Acquisiton	2020-10-06	151,224	$15.00	2,377,025	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2020-10-06	1,525,348	$0.00	1,525,348	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-10-06	700,453	$0.00	700,453	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of theIssuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.
The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.